Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Indometacin + paracetamol is a fixed-dose combination drug containing indometacin (indomethacin), a potent nonsteroidal anti-inflammatory drug (NSAID), and paracetamol (acetaminophen), an analgesic and antipyretic agent. Indometacin acts as a non-selective inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing prostaglandin synthesis to alleviate pain, swelling, and inflammation. Paracetamol acts primarily in the central nervous system to provide additional pain relief and reduce fever. This synergistic combination is indicated for the management of moderate-to-severe pain, fever, and inflammatory conditions such as rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and acute musculoskeletal disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on indometacin + paracetamol.